Osteoporosis drug may strengthen bones from the inside out
NCT ID NCT01155232
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether taking teriparatide (Forteo) for 24 months can improve bone structure in 100 men and women with osteoporosis. Researchers will use a special CT scan to see changes in bone thickness and microarchitecture at the wrist and shin. The goal is to understand how this drug reduces fracture risk beyond just increasing bone density.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teriparatide (Forteo) injection
What this could lead to
If successful, this could show that teriparatide strengthens bones by improving their internal structure, not just density, leading to better fracture prevention.
What could go wrong
This is a small, non-randomized study with 100 participants, so results may not apply to everyone. Bone structure changes may not translate to fewer fractures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network, TGH
Toronto, Ontario, M5G 2C4, Canada